Chapel Hill, NC – According to filings with the U.S. Securities and Exchange Commission, Renovion is raising $7,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Dan Copeland played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Renovion

Renovion is a clinical stage pharmaceutical company with a nebulized therapy that restores mucus clearance and reduces inflammation in the lungs. We are focused on developing ARINA-1 for orphan chronic inflammatory lung diseases. With over 25 patient years of experience, ARINA-1 is poised to start clinical studies in cystic fibrosis, primary ciliary dyskinesia and alpha-1 anti-trypsin deficiency patients.

To learn more about Renovion, visit http://www.renovion.com/

Contact:
Dan Copeland, Chief Executive Officer
919-321-1555
dan@renovion.com
https://www.linkedin.com/in/dancopeland/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved